Nine Square Therapeutics focuses on accelerating the development of novel therapeutics for neurodegenerative diseases. The company pursues challenging and previously undruggable biological targets to create better treatment options. Their approach is driven by innovation to alter the trajectory of serious neurological conditions.
Funding
$50M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MJFounders
Product
Problem
Neurodegenerative diseases pose a significant challenge due to the complex biological mechanisms and the lack of effective drug therapies. Current treatments often fail to address the underlying causes of neuronal dysfunction and cell death. The autophagy-lysosomal pathway, responsible for clearing cellular waste, is often impaired in these diseases, contributing to the accumulation of toxic protein aggregates.
Solution
Nine Square Therapeutics is developing novel drug candidates that target the autophagy-lysosomal pathway to treat neurodegenerative diseases. The company utilizes machine learning-enabled image-based cell profiling to identify and validate promising drug targets. Their approach aims to enhance the clearance of toxic protein aggregates, reduce neuronal dysfunction, and slow disease progression. By focusing on the autophagy-lysosomal pathway, Nine Square Therapeutics seeks to address the underlying causes of neurodegenerative diseases and develop more effective therapies. The company is advancing multiple programs through preclinical development towards IND-enabling studies.
Target Audience
The primary target audience includes patients suffering from neurodegenerative diseases, as well as pharmaceutical companies and research institutions focused on developing new treatments for these conditions.
Features
- Machine learning-enabled image-based cell profiling for target discovery
- Focus on modulating the autophagy-lysosomal pathway
- Development of drug candidates for neurodegenerative diseases
- Preclinical programs targeting specific disease mechanisms